DLBCL

Apr 16, 2024

Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation

Jun 20, 2023

FDA Extended the Review Period for Momelotinib; FDA Approves Roche’s Columvi; Avita Medical Obtains FDA Approval of RECELL; FDA Approves Odevixibat for ALGS; TME Pharma Receives IND Approval for NOX-A12; Aldeyra’s Phase 3 INVIGORATE‑2 Trial of Reproxalap

May 23, 2023

Abbvie-Genmab’s EPKINLY Approval for DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

May 23, 2023

FDA Approves RINVOQ for Crohn’s Disease; FDA Approves Krystal Biotech’s Gene Therapy Vyjuvek; FDA Approves EPKINLY to Treat R/R DLBCL; FDA Orphan Drug Designation to Mitazalimab; Phase 3 Trial Result of OCS-01 Eye Drops; TAGRISSO® + Chemotherapy for the EGFR-mutated Advanced Lung Cancer

Apr 28, 2023

Roche’s CD79b ADC POLIVY: Attempt to Change DLBCL Treatment Space

Feb 24, 2023

Top 10 Expected Oncology Drug Launches in 2023

Jan 31, 2023

Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

Dec 19, 2022

ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges

Dec 16, 2022

ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL

Jan 14, 2022

Most Promising Oncological Drugs Expected to Launch in 2022

Newsletter/Whitepaper